Dalton Transactions Blog

We have just updated our reviewer recommend ‘HOT articles’ & our cummulative 2019 Frontier & Perspective collections.

We update our HOT articles collection quarterly and make the selected articles free to access for 6 weeks! This collection represents the top 10% of research published in Dalton Transactions between April – June 2019.

Make the most of the free to access period by browsing the collection today!

Why not start here:

Rhodium nanoparticles stabilized by ferrocenyl-phosphine ligands: synthesis and catalytic styrene hydrogenation
M. Ibrahim, M. M. Wei, E. Deydier, E. Manoury, R. Poli, P. Lecante and K. Philippot
Dalton Trans., 2019, 48, 6777-6786
DOI: 10.1039/C9DT01006H, Paper

Studies of hysteresis and quantum tunnelling of the magnetisation in dysprosium(III) single molecule magnets
Fabrizio Ortu, Daniel Reta, You-Song Ding, Conrad A. P. Goodwin, Matthew P. Gregson, Eric J. L. McInnes, Richard E. P. Winpenny, Yan-Zhen Zheng, Stephen T. Liddle, David P. Mills and Nicholas F. Chilton
Dalton Trans., 2019, 48, 8541-8545
DOI: 10.1039/C9DT01655D, Communication

Our 2019 Frontier & Perspective collection pulls together all of the reviews published in Dalton Transactions throughout the year. Remember to check back to read our latest articles!

These two articles are already getting citations:

Emerging platinum(IV) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment
Zhigang Wang, Zhiqin Dengac and Guangyu Zhu
Dalton Trans., 2019, 48, 2536-2544
DOI: 10.1039/C8DT03923B, Perspective

Kinetics and mechanisms of catalytic water oxidation
Shunichi Fukuzumi, Yong-Min Lee and Wonwoo Nam
Dalton Trans., 2019, 48, 779-798
DOI: 10.1039/C8DT04341H, Perspective

Submit your work to Dalton Transactions– Check our website for handy tips and guidelines or find out more about the benefits of publishing with the Royal Society of Chemistry.

Vitamin B12 plays an important role in the metabolism of many organisms, particularly mammals.  Since efficient delivery of vitamin B12 into cells has potential applications in medical therapies, Zelder et al. are sure to inspire wider interest in the design, chemistry and biology of backbone modified B12 derivatives with this hot Perspective.

Download the Perspective today for free…

Peptide B12: emerging trends at the interface of inorganic chemistry, chemical biology and medicine
Felix Zelder, Kai Zhou and Marjorie Sonnay
Dalton Trans., 2013
DOI: 10.1039/C2DT32005C

Declan Gaynor and Darren Griffith discuss how medicinal inorganic chemistry is currently flourishing in this Dalton Transactions Perspective.  Understanding the role of metals in biological systems is very important for drug design; the predictability and control of inorganic complexes make fine-tuning the properties of drugs incorporating such complexes a real possibility.  Metal-based compounds are already routinely administered on a regular basis and this Perspective encourages chemists to further investigate inorganic therapeutic and diagnostic medicine by looking at previous successes, e.g. MRI contrast agents, then moving onto current challenges such as antibacterial compounds for tackling hospital acquired infections.

To find out more, you can download the Perspective now – which is free to access for 4 weeks!

The prevalence of metal-based drugs as therapeutic or diagnostic agents: beyond platinum
Declan Gaynor and Darren M. Griffith
Dalton Trans., 2012
DOI: 10.1039/C2DT31601C, Perspective

Also of interest…

Mn(II) complexes of novel hexadentate AAZTA-like chelators: a solution thermodynamics and relaxometric study
Lorenzo Tei, Giuseppe Gugliotta, Marianna Fekete, Ferenc K. Kálmán and Mauro Botta
Dalton Trans., 2011, 40, 2025-2032
DOI: 10.1039/C0DT01114B, Paper

Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals
Sibaprasad Bhattacharyya and Manish Dixit
Dalton Trans., 2011, 40, 6112-6128
DOI: 10.1039/C1DT10379B, Perspective
From themed issue Radiopharmaceuticals for imaging and therapy

The status of platinum anticancer drugs in the clinic and in clinical trials
Nial J. Wheate, Shonagh Walker, Gemma E. Craig and Rabbab Oun
Dalton Trans., 2010, 39, 8113-8127
DOI: 10.1039/C0DT00292E, Perspective

Are you following us on Twitter? @DaltonTrans

Wilson’s disease is a rare genetic condition caused by inheriting an abnormal copy of the Wilson disease protein (ATP7B) gene. The disease affects approximately 1-4 people per 100,000 and prevents sufferers from regulating the concentration of copper within their body, inducing a copper overload.

The redox properties of copper make it a very important metal biologically and it is involved in a wide range of enzymatic processes. The anti-oxidant enzyme superoxide dismutase for example is expressed in all cells and is part of our anti-oxidant defence, while the more specialised dopamine β-hydroxylase is only expressed in the brain and is involved in dopamine conversion. Balancing the amount of copper we have in our bodies is crucial for good health, having a copper deficit would hinder vital functions, but having an excess can cause oxidative stress by promoting the formation of hydroxyl radicals.

Designing new drugs to treat Wilson’s disease which can be targeted to the liver, where excess copper is found

Treating Wilson’s disease involves life-long chelation therapy, this is the application of compounds designed to bind to the excess copper ions and allow them to be safely excreted. This Hot Perspective by Pascale Delangle and Elisabeth Mintz reviews the drugs currently in use and gives insight in to the development of more advanced treatments, highlighting the design of bio-inspired chelating agents and drug targeting.

l
To find out more you can download this article now, which is free to access for 4 weeks!
l
lll
Chelation therapy in Wilson’s disease: from D-penicillamine to the design of selective bioinspired intracellular Cu(I) chelators
Pascale Delangle and Elisabeth Mintz
Dalton Trans., 2012, Advance Article
DOI: 10.1039/C2DT12188C

l

To stay up to date with the latest news in inorganic chemistry you can also follow us on twitter and sign up to our e-alert service.

Edward Tiekink is based at the University of Malaya

Edward Tiekink gives us a concise overview of drug developments involving selenium and tellurium compounds in this Dalton Transactions Frontier.

Download it today, whilst it is still free….

Therapeutic potential of selenium and tellurium compounds: Opportunities yet unrealised
Edward R. T. Tiekink
Dalton Trans., 2012
DOI: 10.1039/C2DT12225A

Why not take a look at some of Edward Tiekink’s other recent articles:

The metal–carbonyl···π(aryl) interaction as a supramolecular synthon for the stabilisation of transition metal carbonyl crystal structures
Julio Zukerman-Schpector, Ionel Haiduc and Edward R.T. Tiekink
Chem. Commun., 2011, 47, 12682-12684
DOI: 10.1039/C1CC15579B, Communication

Interwoven coordination polymers sustained by tautomeric forms of the bridging ligand
Pavel Poplaukhin and Edward R. T. Tiekink
CrystEngComm, 2010, 12, 1302-1306
DOI: 10.1039/B916585A, Paper

Kenneth Kam-Wing Lo

The rich photophysical properties of luminescent inorganic and organometallic transition metal complexes, such as their intense, long-lived, and environment-sensitive emission, make them excellent candidates for biological and cellular probes. In this Dalton Transactions Perspective, Ken Lo and colleagues review examples of biological probes derived from luminescent transition metal complexes with a d6, d8, or d10 metal center.  Also discussed is the possible use of luminescent transition metal complexes as photodynamic therapeutics for various diseases or even light-activated drug release moelcules.

Applications of luminescent inorganic and organometallic transition metal complexes as biomolecular and cellular probes
Kenneth Kam-Wing Lo, Alex Wing-Tat Choi and Wendell Ho-Tin Law
Dalton Trans., 2012, DOI: 10.1039/C2DT11892

K